Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Hershey Co (HSY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Hershey Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Hershey Co trades at $173.97 (market cap $35.23B). The key difference: Alnylam Pharmaceuticals, Inc. and Hershey Co are close in size by market cap, and Hershey Co pays a 3.34% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HSY | |
|---|---|---|
Market Cap | $39.89B | $35.23B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $236.28 |
52-Week Low | $278.09 | $162.31 |
Enterprise Value | $38.15B | $40.03B |
Dividend Yield | — | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
HSY trades at $173.66, up 1.17% with recent earnings beats and easing cocoa costs supporting fundamentals. Technicals are bearish with resistance at $175, while valuation metrics like a P/E of 32.34 suggest premium pricing. The company maintains strong cash flow and a 3.22% dividend yield, with Q2 2026 earnings due July 30, 2026, as a key catalyst.
Outlook: Upside exists to the $210.33 consensus target if margin recovery continues, but high debt and volatile input costs pose risks. Analyst sentiment is cautious with 65.7% hold ratings, reflecting balanced growth and valuation concerns amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
